Aragon obtains $42M in funding for cancer drug development

03/7/2012 | Genetic Engineering & Biotechnology News

Aragon Pharmaceuticals secured $42 million in a Series C funding round headed by new investor Topspin Fund. The money will be used to advance the development of Aragon's early clinical and preclinical androgen receptor- and estrogen receptor-targeting drugs for certain prostate and breast cancers.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI